April 1st 2025, 9:00pm
By Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
April 1st 2025, 8:00pm
By Alison Silberman
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
April 1st 2025, 7:05pm
By Ryan Scott
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal cancers.
April 1st 2025, 5:49pm
By Chester Freeman
As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical challenges.
April 1st 2025, 4:24pm
The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the global phase 3 MIRACLE trial.
April 1st 2025, 3:00pm
Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.
April 1st 2025, 1:13pm
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.
March 31st 2025, 9:00pm
By Dr. William C. Huang
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
March 31st 2025, 8:00pm
By Spencer Feldman
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
March 31st 2025, 7:00pm
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
March 31st 2025, 5:00pm
By Karen Cohn
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
March 31st 2025, 4:02pm
A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.
March 31st 2025, 3:29pm
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.
March 31st 2025, 1:00pm
By Lisa Craine
I’ve spent 14 years navigating recovery, mental health challenges and giving back to the cancer community through patient mentorship.
March 30th 2025, 6:00pm
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.
Bringing Together the CAR T-Cell Therapy Community
Nutrition is Key Following a Cancer Diagnosis
The Leukemia & Lymphoma Society is Helping Patients With Medial Debt
Insights into the Latest Trends in Pancreatic Cancer